

May 6, 2024

<b>BSE Limited</b> P J Towers, Dalal Street, <u>Mumbai-400001</u>	<b>Code: 532321</b>	<b>National Stock Exchange of India Limited</b> <b>Code: Zyduslife</b> Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>
--	---------------------	--

**Re.: Sale of stake of Bayer Zydus Pharma Private Limited**

**Ref.: 1. Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) read with SEBI Circular dated July 13, 2023**

**2. Our earlier intimation dated May 2, 2024**

Dear Sir / Madam,

In our earlier intimation dated May 2, 2024, we had intimated that pursuant to the joint venture agreement, Zydus Lifesciences Limited (“the **Company**”) had entered into a share purchase agreement (“**SPA**”) with Bayer Pharmaceuticals Private Limited (“the **Purchaser**”) and Bayer Zydus Pharma Private Limited (“the **JV Company**”) for sale and transfer of 1,24,99,999 equity shares of Rs. 10/- (“**Sale Shares**”) of the JV Company, held by the Company to the Purchaser and the said transaction will be completed within a period of ten days from the date of execution of the SPA.

This is to update that the Company has received the consideration amount towards the sale and transfer of Sale Shares and the Sale Shares are transferred to the Purchaser. In view of the same, Bayer Zydus Pharma Private Limited ceases to be the joint venture of the Company.

The transaction is considered to be consummated today.

Please find the same in order.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878

